Latest News
Guardant Health and Merck enter multi-year oncology diagnostics collaboration
19 January 2026 - Precision oncology company Guardant Health Inc (Nasdaq: GH) announced on Monday that it has entered into a multi-year strategic collaboration with pharmaceutical firm Merck, known as MSD outside the United States and Canada, to supp...
Akeso secures NMPA review acceptance for gumokimab in ankylosing spondylitis
19 January 2026 - Biopharmaceutical company Akeso Inc (HKEX: 9926.HK) announced on Monday that the National Medical Products Administration Center for Drug Evaluation has accepted its supplemental New Drug Application for gumokimab (AK111), a humanis...
EMA validates Daiichi Sankyo's ENHERTU plus pertuzumab application for first-line HER2 positive metastatic breast cancer
19 January 2026 - Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) announced on Monday that the European Medicines Agency has validated a Type II Variation marketing authorisation application for ENHERTU (trastuzumab deruxtecan) in combin...
Immunovia gains California approval for PancreaSure and begins commercial rollout
19 January 2026 - Pancreatic cancer diagnostics company Immunovia AB (STO:IMMNOV) announced on Monday that it has received regulatory approval to offer its PancreaSure test commercially in California, marking a key milestone in its three-phase launch...
US FDA accepts Advicenne's NDA for Sibnayal to treat dRTA
19 January 2026 - Advicenne (Euronext Growth Paris:ALDVI), a specialty pharmaceutical company focused on rare kidney diseases, announced on Monday that the US Food and Drug Administration (FDA) has accepted for review its New Drug Application for Sib...